This company no longer operates independently (acquired, merged, or ceased operations). This profile is retained for reference.
Clinical-stage biotech developing TSND-201 (methylone), a rapid-acting neuroplastogen for PTSD and other psychiatric conditions that targets monoamine transporters without 5-HT2A (hallucinogenic) activity. TSND-201 received FDA Breakthrough Therapy designation in July 2025, had Phase 2 IMPACT-1 results published in JAMA Psychiatry in February 2026, and advanced into Phase 3. In 2026 Transcend was acquired by Otsuka Pharmaceutical.